Thu, Apr 17, 2014, 6:13 AM EDT - U.S. Markets open in 3 hrs 17 mins


% | $
Quotes you view appear here for quick access.

Assured Guaranty Ltd. Message Board

vskomarovsky 126 posts  |  Last Activity: Apr 13, 2014 5:31 PM Member since: Feb 9, 2006
  • Reply to

    #RaceToYes White House Petition

    by christine.mcsherry Mar 1, 2014 12:24 PM
    vskomarovsky vskomarovsky Mar 2, 2014 2:33 PM Flag


    Sentiment: Strong Buy

  • vskomarovsky by vskomarovsky Mar 2, 2014 12:31 PM Flag

    The war between the science and the bureaucracy, between truth and lie, passion and negligence. This is the war of the despairing families against the government. The war against time. Against death. The war for life. Children's life. Goodness will conquer corruption. And justice will prevail.

  • vskomarovsky vskomarovsky Mar 1, 2014 3:27 PM Flag

    Isn't this leads to MONEY as a catalyst?

  • Reply to

    #RaceToYes White House Petition

    by christine.mcsherry Mar 1, 2014 12:24 PM
    vskomarovsky vskomarovsky Mar 1, 2014 3:13 PM Flag

    My wife and I signed, and I've sent the site to my sons to sign.

  • Reply to

    #RaceToYes White House Petition

    by christine.mcsherry Mar 1, 2014 12:24 PM
    vskomarovsky vskomarovsky Mar 1, 2014 2:17 PM Flag

    We'll do. You may try the Big PRESS - 60 Minutes, Barbara Walter, Investigative Report and others.

  • - is indicative of a HOPE being secretly warranted.

  • Reply to

    what do you assume?

    by simp08801 Mar 1, 2014 12:19 PM
    vskomarovsky vskomarovsky Mar 1, 2014 1:58 PM Flag

    Yeah, FDA are unreasonable #$%$ - always - holes.

  • Reply to


    by fenway8888 Feb 27, 2014 9:07 AM
    vskomarovsky vskomarovsky Feb 27, 2014 9:20 AM Flag

    A hopeful tone of the presentation. FDA will respond positively in March. Partnership is desirable for all venues, but DMD. Next week SP will go up.

    Sentiment: Buy

  • vskomarovsky vskomarovsky Feb 26, 2014 12:08 PM Flag

    Brilliant assumption.

  • Reply to


    by greyzone513 Feb 25, 2014 3:46 PM
    vskomarovsky vskomarovsky Feb 25, 2014 6:06 PM Flag

    bf - your ability to script a dramatic outcome is a rarity. I'm WATCHING your messages.

    Sentiment: Strong Buy

  • vskomarovsky vskomarovsky Feb 25, 2014 9:24 AM Flag

    He sounds like he is dead.

  • vskomarovsky by vskomarovsky Feb 24, 2014 9:37 PM Flag

    It's Faster... with 3D printing, the delay between design and fabrication is now a few hours instead of a few weeks. Motorcycle maker Ducati cut 20 months (or 70%) off its usual development time for a new racing engine.

    It's Cheaper... companies that use 3D printing don't need to tie up capital investing in expensive tools and dies. They can also eliminate shipping costs. A small supplier to Nike called Union Footwear got a leg up on its bigger competitors by faxing its design bid in 3D.

    It Encourages Innovation... by eliminating the delays and costs created by traditional "manufacturability" constraints, 3D printers allow designers to change their minds and implement a new idea at any time. An Ohio company that supplies crash test dummies to automakers is using the technology to produce new shapes and sizes that respond to client needs that can evolve by the day.

    It's Less Wasteful... traditional manufacturing is "subtractive," discarding up to 90% of the initial blocks of raw material. 3D printing is an "additive" process that builds objects from the ground up, layer by layer. One architect is even using it to make entire buildings.

    It's More Durable... designers can tweak these "additive" printers to produce denser (but lighter) layers of material than would usually be possible. The Smithsonian is using 3D printers to digitize their entire collection; the statue of Thomas Jefferson you see in the National Museum of American History in Washington, DC is actually a 3D replica of the original brass statue.

    It's Customer Friendly... 3D printing allows for a level of product customization and personalization that has never before been possible. Shoppers are already ordering lamps, jewelry, sunglasses, and even bikini swimsuits, all made to their exact specifications. (I know I won't miss having to try on shoes at the mall.)

    Sentiment: Buy

  • Reply to

    Pending Lawsuit and Upcoming Binary Events

    by larrybird111111 Feb 24, 2014 2:23 PM
    vskomarovsky vskomarovsky Feb 24, 2014 4:21 PM Flag

    Bird, you may invest ... into IQ

    Sentiment: Strong Buy

  • Reply to

    decision to acquire Digital PlaySpace

    by relicdriver Feb 20, 2014 6:42 PM
    vskomarovsky vskomarovsky Feb 20, 2014 6:48 PM Flag

    80.56 +4.48(5.89%) - market's reaction.

    Sentiment: Buy

  • vskomarovsky vskomarovsky Feb 20, 2014 6:41 PM Flag

    Assume - I'm FDA. I"ve made a deadly mistake. Hid it for a while, playing in a dark, but my victim turned all the lights up. I am exposed and now I am in troubles. The truth is taking over... Shell I ignore all that? Aren't I Almighty? The hell - I am FDA, and I am above the common sense. Yet, Instinct tells me that this time my usually unquestioned judgement may not be excepted. I am loosing... No! ...Eureka! Play along. Give them what they want... Aren't I wise?

    Sentiment: Strong Buy

  • Reply to


    by thigrlsrk Feb 19, 2014 9:19 PM
    vskomarovsky vskomarovsky Feb 20, 2014 12:37 AM Flag


  • Reply to

    FDA's conundrum

    by bf109gee Feb 19, 2014 12:45 PM
    vskomarovsky vskomarovsky Feb 19, 2014 1:58 PM Flag

    Sarepta's 120-week excellent data is FDA's major discharge off the Nov.12 guilt.

    Sentiment: Strong Buy

  • Reply to

    DDD: I'd be less Optimistic

    by anotherenigma Feb 5, 2014 6:36 PM
    vskomarovsky vskomarovsky Feb 18, 2014 1:32 PM Flag

    another -thumb down and 'ignore'.

    Sentiment: Buy

  • Reply to

    Race to Say YES

    by christine.mcsherry Feb 14, 2014 9:43 AM
    vskomarovsky vskomarovsky Feb 17, 2014 12:46 PM Flag

    You are a paid schmuck with scripted by shorts' pseudo-meaningful statements to which the price is ZERO. Get lost, moron.

  • vskomarovsky by vskomarovsky Feb 14, 2014 4:20 PM Flag

    Summary of Recommendations
    • Recommendation 1:
    The FDA should expand the use of accelerated
    approval for therapies intended to treat rare
    diseases, including Duchenne muscular dystrophy.
    • Recommendation 2:
    The FDA should expand the scope of acceptable
    endpoints, including novel surrogate and
    intermediate clinical endpoints, used to approve
    drugs for serious or life-threatening diseases with
    unmet medical need, such as Duchenne.
    • Recommendation 3:
    Using existing authority under current law, the
    FDA should pilot the use of adaptive approval
    for serious and life-threatening disorders with
    significant unmet medical need.
    • Recommendation 4:
    The FDA should give greater weight to the
    demonstrated benefit/risk preferences of patients,
    as well as caregivers in the case of pediatric illness,
    when making benefit/risk determinations.
    The need for strong, reliable clinical data
    demonstrating substantial evidence of safety and
    efficacy is of critical importance for the review and
    approval of new drugs. In weighing these data during
    the evaluation of new drugs, the FDA must determine
    in each case whether the benefits appear to outweigh
    the known risks. Striking the correct balance between
    the need for more data and access to new, potentially
    beneficial treatments is the constant challenge set
    before the Agency. To successfully navigate this
    challenge, it is imperative that the FDA adhere to
    its own guidance calling for the consideration of the
    relative lethality and the seriousness of the disorder the
    drug is designed to treat, as well as the availability or
    lack of alternative treatments. These considerations will
    vary substantially from one disorder to another, and it is
    often the case that patients’ risk tolerance increases in
    relation to the morbidity and mortality associated with
    a particular illness.31 To date, however, there has been
    little indication that the FDA is inclined to utilize the
    significant discretion at its disposal in reviewing drugs
    for Duchenne.
    The passage of FDASIA and its implementation over
    the next several years have created new opportunities
    for the FDA to speed responsible access to new
    therapies for Duchenne and other rare, serious and
    life-threatening disorders. The FDA must seize this
    opportunity to issue guidance providing clear and
    accessible standards for the application of accelerated
    approval to therapies for Duchenne, and it should
    move immediately to better incorporate the patient
    perspective into its assessment of an appropriate
    benefit/risk ratio. PPMD and the distinguished panel of
    advisors who contributed to this report stand ready to
    work alongside the FDA to strike a more appropriate
    balance between clinical certainty and patient access
    to potentially life-saving treatments. Patients and
    their families, frustrated by the slow pace of progress
    and desperate for access to new treatments for this
    devastating illness, deserve nothing less.

    Sentiment: Strong Buy

23.91+0.24(+1.01%)Apr 16 4:01 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.